Investigational drug · Phase 2
XP-102
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cancer, BRAF V600 Mutation, Melanoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "XP-102"
First trial start
2025
Dec 31, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XP-102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cancer
- BRAF V600 Mutation
- Melanoma
- Colorectal Cancer
- Thyroid Cancer
- Nonsmall Cell Lung Cancer
Approved drugs for the same conditions: Small cell lung cancer · Colorectal cancer · Melanoma · Thyroid cancer · Oncology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "XP-102" as an intervention, largest first.
- XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 MutationNot yet recruiting
Xynomic Pharmaceuticals, Inc.Industry
NCT05275374 · 221 participants (planned) · Start Dec 31, 2025 · Primary completion Dec 30, 2027
Drug: XP-102; Trametinib · For: Cancer; BRAF V600 Mutation; Melanoma and 3 more
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Cancer
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- DivarasibGDC-6036, RO7435846Phase 38 trials
Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- anzutresgene autoleucelIMA203 Product, IMA203 product- flat dosePhase 32 trials
Immatics US, Inc. · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- EmactuzumabPhase 32 trials
Roche (Genentech) · Cancer, TGCT
- GFH276Phase 25 trials
Genfleet Therapeutics (Shanghai) Inc. · RAS Mutation, Pancreatic Cancer, Non-small Cell Lung Cancer (NSCLC)
- ADCAntibody-drug conjugate, ADCE-D01Phase 23 trials
MBrace Therapeutics · Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.